Literature DB >> 15123463

Squamous cell carcinoma related oncogene regulates angiogenesis through vascular endothelial growth factor-A.

Simon G Talbot1, Pornchai O-charoenrat, Inderpal S Sarkaria, Ronald Ghossein, Pabbathi Reddy, Ivan Ngai, Christina N Cordeiro, Richard J Wong, Mark G Kris, Valerie W Rusch, Bhuvanesh Singh.   

Abstract

BACKGROUND: Squamous cell carcinoma related oncogene expression (SCCRO) correlates with vascular endothelial growth factor-A expression. This data is validated in human lung tumors and provides a putative pathway for angiogenesis in a subset of squamous cell carcinomas. Squamous cell carcinoma related oncogene is a novel oncogene identified by positional cloning of a recurrent amplification at 3q26.3. It is over-expressed in 39.8% of lung, head and neck, cervical, and ovarian carcinomas. SCCRO imparts an aggressive phenotype to affected cancers, which may be related to increased angiogenesis due to SCCRO expression. Our previous work has demonstrated a link between SCCRO and vascular endothelial growth factor-A (VEGF-A) expression in vitro, suggesting a mechanism for SCCRO-induced angiogenesis. The present study aims to confirm and validate this link between SCCRO and VEGF-A expression in an ex vivo human tumor cohort.
METHODS: Fresh tissue was collected at Memorial Sloan-Kettering Cancer Center from 34 patients undergoing primary resection of lung squamous cell carcinomas. RNA was extracted from this tissue, reverse-transcribed, and real-time polymerase chain reaction (RT-PCR) was carried out using a BioRad iQ iCycler with SYBR green fluorophore. Microvessel counting was performed on the tumor specimens using CD34 immunohistochemistry.
RESULTS: The expression of both SCCRO and VEGF-A mRNA varies widely in both tumor and normal tissue. SCCRO and VEGF-A co-expression was significantly correlated (R(2) = 0.63; P < 0.032). Microvessel counts were not associated with expression of SCCRO or VEGF-A and failed to significantly predict survival. VEGF-A expression in this patient group is a predictor of overall survival (P < 0.032).
CONCLUSIONS: VEGF-A expression correlates with SCCRO expression in these primary human lung squamous cell carcinomas and is a predictor of clinical behavior. This data supports the association of SCRRO and VEGF-A in the induction of angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15123463     DOI: 10.1245/ASO.2004.03.014

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  5 in total

1.  SCCRO promotes glioma formation and malignant progression in mice.

Authors:  Stephen R Broderick; Benjamin J Golas; Duykhanh Pham; Christopher W Towe; Simon G Talbot; Andrew Kaufman; Sarina Bains; Laryssa A Huryn; Yoshihiro Yonekawa; Diane Carlson; Dolores Hambardzumyan; Yegnanarayana Ramanathan; Bhuvanesh Singh
Journal:  Neoplasia       Date:  2010-06       Impact factor: 5.715

2.  Discovery of Novel Pyrazolo-pyridone DCN1 Inhibitors Controlling Cullin Neddylation.

Authors:  Ho Shin Kim; Jared T Hammill; Daniel C Scott; Yizhe Chen; Jaeki Min; Jonah Rector; Bhuvanesh Singh; Brenda A Schulman; R Kiplin Guy
Journal:  J Med Chem       Date:  2019-09-13       Impact factor: 7.446

3.  Discovery of an Orally Bioavailable Inhibitor of Defective in Cullin Neddylation 1 (DCN1)-Mediated Cullin Neddylation.

Authors:  Jared T Hammill; Deepak Bhasin; Daniel C Scott; Jaeki Min; Yizhe Chen; Yan Lu; Lei Yang; Ho Shin Kim; Michele C Connelly; Courtney Hammill; Gloria Holbrook; Cynthia Jeffries; Bhuvanesh Singh; Brenda A Schulman; R Kiplin Guy
Journal:  J Med Chem       Date:  2018-03-26       Impact factor: 7.446

4.  Pathophysiology of age-related diseases.

Authors:  Giuseppina Campisi; Martina Chiappelli; Massimo De Martinis; Vito Franco; Lia Ginaldi; Rosario Guiglia; Federico Licastro; Domenico Lio
Journal:  Immun Ageing       Date:  2009-09-08       Impact factor: 6.400

5.  Immunohistochemical Expression of DCUN1D1 in Non-small Cell Lung Carcinoma: Its Relation to Brain Metastasis.

Authors:  Jinyoung Yoo; Seong-Hak Lee; Kwang-Il Lym; Sonya Youngju Park; Seung-Ho Yang; Chang-Young Yoo; Ji-Han Jung; Seok-Jin Kang; Chang-Suk Kang
Journal:  Cancer Res Treat       Date:  2012-03-31       Impact factor: 4.679

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.